Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Søndergaard, Jonas N ^a,e   Nazarian, Ramin ^a   Wang, Qi ^a   Guo, Deliang ^a   Hsueh, Teli ^a   Mok, Stephen ^a   Sazegar, Hooman ^a   MacConaill, Laura E ^b,c   Barretina, Jordi G ^b,c   Kehoe, Sarah M ^b,c   Attar, Narsis ^a   von Euw, Erika ^a   Zuckerman, Jonathan E ^a   Chmielowski, Bartosz ^a   Comin Anduix, Begoña ^a   Koya, Richard C ^a   Mischel, Paul S ^a,d   Lo, Roger S ^a,d   Ribas, Antoni ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; MITOGEN ACTIVATED PROTEIN KINASE; PLX 4032; RO 5185426; TRACER; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL MUTANT; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME INHIBITION; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; GENOME ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MASS SPECTROMETRY; MELANOMA; MELANOMA CELL; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; POSITRON EMISSION TOMOGRAPHY; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; AMINO ACID SUBSTITUTION; ANIMAL; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; DIAGNOSTIC IMAGING; DRUG ANTAGONISM; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENETICS; HUMAN GENOME; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACID SUBSTITUTION; ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DIAGNOSTIC IMAGING; DRUG RESISTANCE, NEOPLASM; GENOME, HUMAN; HUMANS; INDOLES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950954465     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-39     Document Type: Article

References (26)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857. 10.1038/nature05661, 17314971.
2. Smalley KS, Nathanson KL, Flaherty KT. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 2009, 69:3241-3244. 10.1158/0008-5472.CAN-08-4305, 19351826.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
4. Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol 2008, 20:183-189. 10.1097/CCO.0b013e3282f5271c, 18300768.
5. Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol 2007, 25:1606-1620. 10.1200/JCO.2006.06.0442, 17443002.
6. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006, 12:2301s-2307s. 10.1158/1078-0432.CCR-05-2518, 16609049.
7. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147. 10.1056/NEJMoa050092, 16291983.
8. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867. 10.1016/S0092-8674(04)00215-6, 15035987.
9. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008, 105:3041-3046. 10.1073/pnas.0711741105, 2268581, 18287029.
10. Kumar R, Angelini S, Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene 2003, 22:9217-9224. 10.1038/sj.onc.1206909, 14681681.
11. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007, 39:347-351. 10.1038/ng1975, 17293865.
12. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, Hakonarson H, Bucan M. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 2007, 17:1665-1674. 10.1101/gr.6861907, 2045149, 17921354.
13. Comin-Anduix B, Boros LG, Marin S, Boren J, Callol-Massot C, Centelles JJ, Torres JL, Agell N, Bassilian S, Cascante M. Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells. J Biol Chem 2002, 277:46408-46414. 10.1074/jbc.M206150200, 12351627.
14. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci USA 2009, 106:12932-12937. 10.1073/pnas.0906606106, 2714280, 19625624.
15. Shu CJ, Radu CG, Shelly SM, Vo DD, Prins R, Ribas A, Phelps ME, Witte ON. Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. Int Immunol 2009, 21:155-165. 10.1093/intimm/dxn133, 2638874, 19106231.
16. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, Conrads TP, Veenstra TD, Lu KP, Morrison DK. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 2005, 17:215-224. 10.1016/j.molcel.2004.11.055, 15664191.
17. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009, 106:4519-4524. 10.1073/pnas.0900780106, 2649208, 19251651.
18. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221. 10.1016/j.cell.2009.12.040, 20141835.
19. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464(7287):427-30. 10.1038/nature08902, 20179705.
20. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, Cantley LC. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009, 33:237-247. 10.1016/j.molcel.2008.12.026, 2715556, 19187764.
21. Radu CG, Shu CJ, Nair-Gill E, Shelly SM, Barrio JR, Satyamurthy N, Phelps ME, Witte ON. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog. Nat Med 2008, 14:783-788. 10.1038/nm1724, 2720060, 18542051.
22. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008, 6:751-759. 10.1158/1541-7786.MCR-07-2001, 18458053.
23. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008, 68:4853-4861. 10.1158/0008-5472.CAN-07-6787, 2692356, 18559533.
24. Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, Adjei AA. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 2008, 68:6145-6153. 10.1158/0008-5472.CAN-08-1430, 18676837.
25. Boisvert-Adamo K, Aplin AE. Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene 2008, 27:3301-3312. 10.1038/sj.onc.1211003, 18246127.
26. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009, 27(15s). suppl; abstr 9000.